We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

130 hedge funds and large institutions have $732M invested in Revance Therapeutics, Inc. in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more call options, than puts

Call options by funds: $1.66M | Put options by funds: $869K

37% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 38

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 21

3% less funds holding

Funds holding: 134 → 130 (-4)

12% less capital invested

Capital invested by funds: $828M → $732M (-$96.2M)

Holders
130
Holders Change
-4
Holders Change %
-2.99%
% of All Funds
2.86%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
19
Increased
52
Reduced
38
Closed
21
Calls
$1.66M
Puts
$869K
Net Calls
+$791K
Net Calls Change
+$1.23M

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$35.2M
2
Goldman Sachs
Goldman Sachs
New York
+$12.9M
3
PAI
Palo Alto Investors
California
+$10.9M
4
BlackRock
BlackRock
New York
+$6.59M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$5.4M

Top Sellers

Rank Fund Capital Flow
1
ACH
ArrowMark Colorado Holdings
Colorado
-$21.7M
2
NCM
NovaQuest Capital Management
North Carolina
-$19.8M
3
PC
Polar Capital
United Kingdom
-$15M
4
DM
Deerfield Management
New York
-$14.6M
5
BAMCO Inc
BAMCO Inc
New York
-$6.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCG
126
Private Capital Group
Connecticut
$1K – – –
S
127
SignatureFD
Georgia
$1K – – –
BAM
128
Bellevue Asset Management
Washington
$1K +$703 +34 +103%
TPCW
129
TD Private Client Wealth
New York
$503 – – –
DM
130
Deerfield Management
New York
– -$14.6M -900,000 Closed
Alyeska Investment Group
131
Alyeska Investment Group
Illinois
– -$6.46M -398,362 Closed
Point72 Asset Management
132
Point72 Asset Management
Connecticut
– -$4.3M -265,199 Closed
PCM
133
Pinz Capital Management
New York
– -$3.64M -224,000 Closed
MS
134
Maven Securities
Jersey
– -$2.36M -146,498 Closed
Millennium Management
135
Millennium Management
New York
– -$1.77M -109,199 Closed
SCM
136
Sio Capital Management
New York
– -$1.42M -87,700 Closed
MIM
137
Monashee Investment Management
Massachusetts
– -$1.38M -85,000 Closed
Jacobs Levy Equity Management
138
Jacobs Levy Equity Management
New Jersey
– -$1.06M -65,176 Closed
VC
139
Voss Capital
Texas
– -$730K -45,000 Closed
OAM
140
Oxford Asset Management
United Kingdom
– -$342K -21,082 Closed
RCG
141
Rock Creek Group
District of Columbia
– -$243K -15,000 Closed
EGM
142
Engineers Gate Manager
New York
– -$210K -12,931 Closed
Invesco
143
Invesco
Georgia
– -$193K -11,866 Closed
ECM
144
ExodusPoint Capital Management
New York
– -$191K -11,765 Closed
Simplex Trading
145
Simplex Trading
Illinois
– -$182K -8,814 Closed
TRCT
146
Tower Research Capital (TRC)
New York
– -$48K -2,970 Closed
CG
147
Cutler Group
California
– -$21K -1,300 Closed
FIA
148
FNY Investment Advisers
New York
– -$16K -1,000 Closed
EW
149
Evoke Wealth
California
– -$6.91K -426 Closed
BRC
150
Bell Rock Capital
Delaware
– -$1K -100 Closed
3 4 5
6
7

RVNC Hedge Fund Activity: Q1 2020 in Review

130 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2020, worth a combined $732M — down 12% from $828M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of RVNC and 19 opened new positions — a net loss of 2 holders — while 38 trimmed existing stakes and 52 added.

The largest buyer was Jennison Associates, opening a new position worth an estimated $35.2M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $21.7M.

  • 130 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2020, down from 134 in Q4 2019.
  • Funds reported $732M of Revance Therapeutics, Inc. stock for Q1 2020, down 12% quarter-over-quarter.
  • 19 funds opened new Revance Therapeutics, Inc. positions in Q1 2020 and 21 closed out, a net change of -2 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q1 2020 was Jennison Associates, an estimated $35.2M added.
  • The largest Revance Therapeutics, Inc. seller in Q1 2020 was ArrowMark Colorado Holdings, an estimated $21.7M sold.

Based on aggregated 13F filings for Q1 2020.